Edgewise Therapeutics (EWTX) Accounts Payables (2020 - 2026)

Edgewise Therapeutics has disclosed Accounts Payables across 7 years of filings, most recently posting $7.3 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $7.3 million, down 17.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (down 17.02% YoY), and the FY2025 annual result was $6.0 million, up 7.65% from the prior year.
• Accounts Payables came in at $7.3 million for Q1 2026 at Edgewise Therapeutics, up from $6.0 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.8 million in Q1 2025 to a low of $2.8 million in Q2 2022.
• The 5-year median for Accounts Payables is $5.6 million (2024), against an average of $5.7 million.
• Across the five-year window, Accounts Payables jumped 229.43% in 2022 and slumped 34.07% in 2023, its largest moves.
• Edgewise Therapeutics' Accounts Payables stood at $6.1 million in 2022, then sank by 34.07% to $4.0 million in 2023, then jumped by 38.61% to $5.6 million in 2024, then advanced by 7.65% to $6.0 million in 2025, then grew by 21.43% to $7.3 million in 2026.
• The last three Accounts Payables figures came in at $7.3 million (Q1 2026), $6.0 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.